A Study of Treatment Delivery Preference In People With Kidney Cancer

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT07872553
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab Injectable Product — DRUG
    Participants will be randomized to receive nivolumab subcutaneously
  • Nivolumab — DRUG
    Participants will be randomized to receive Nivolumab intravenously
  • Pembrolizumab injection — DRUG
    Participants will be randomized to receive Pembrolizumab subcutaneously
  • Pembrolizumab — DRUG
    Participants will be randomized to receive Pembrolizumab intravenously

Study Details

The purpose of this study is to see if people prefer immunotherapy treatment for kidney cancer delivered intravenously or subcutaneously and if it is practical for participants to receive labs at home and have a video (telehealth) visit with their doctor prior to their day of treatment.

Key Dates

First listed
Oct 13, 2026
Start date
Sep 24, 2026
Status verified
Oct 2026
Primary completion
Sep 24, 2030
Completion
Sep 24, 2030

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Participants receiving IV nivolumab/NIVO or pembrolizumab/PEMBRO
    Participants will be randomized to receive IV nivolumab/NIVO or pembrolizumab/PEMBRO
  • Experimental: Participants receiving subcutaneous nivolumab/NIVO or pembrolizumab/PEMBRO
    Participants will be randomized to receive subcutaneous nivolumab/NIVO or pembrolizumab/PEMBRO

Primary Outcome Measure

Part I: Participants preference between intravenous/IV vs subcutaneous/SC immune checkpoint inhibitor (NIVO and PEMBRO) for Renal Cell Carcinoma. [ Time Frame: 1 year ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking RidgeNew Jersey07920
Sahil Doshi, MD
646-422-4341
Memorial Sloan Kettering Monmouth (All Protocol Activities)MiddletownNew Jersey07748
Sahil Doshi, MD
646-422-4341
Memorial Sloan Kettering Bergen (All Protocol Activities)MontvaleNew Jersey07645
Sahil Doshi, MD
646-422-4341
Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities)CommackNew York11725
Sahil Doshi, MD
646-422-4341
Memorial Sloan Kettering Westchester (All Protocol Activities)HarrisonNew York10604
Sahil Doshi, MD
646-422-4341
Memorial Sloan Kettering Cancer Center (All Protocol Activites)New YorkNew York10065
Sahil Doshi, MD
646-422-4341
Memorial Sloan Kettering Nassau (All Protocol Activities)UniondaleNew York11553
Sahil Doshi, MD
646-422-4341

Find similar trials in Basking Ridge, NJ

Nationwide
Kidney cancer trialsOncology trialsUrology trials
By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (All Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (All Protocol Activities)· Montvale, NJMemorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities)· Commack, NYMemorial Sloan Kettering Westchester (All Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center (All Protocol Activites)· New York, NY

Related Studies